- What the DACVCP Credential Actually Is
- The Two-Phase Path to Board Certification
- Training, Eligibility and the Publication Requirement
- How Phase I Is Built and Delivered
- How Phase II Differs
- The Content Map: Domains You Must Master
- Fees, Deadlines and the Five-Year Window
- Sequencing Domains Across Your Preparation
- Who Hires Clinical Pharmacologists
- Maintaining the Credential
- Frequently Asked Questions
- DACVCP designates a Diplomate of the American College of Veterinary Clinical Pharmacology, certified through separate Phase I and Phase II examinations.
- Phase I is 200 multiple-choice questions in two 100-question sessions; Phase II is ten question groups worth 200 points.
- Phase II eligibility requires two peer-reviewed papers accepted or published by February 1 of the examination year.
- Both phases must be passed within a five-year eligibility window that starts after Phase I approval.
What the DACVCP Credential Actually Is
DACVCP stands for Diplomate, American College of Veterinary Clinical Pharmacology. It is the board-certified specialty credential administered by the American College of Veterinary Clinical Pharmacology (ACVCP), the organization that sets the training, examination and credentialing standards for veterinary clinical pharmacologists. Holding the designation signals that a veterinarian completed approved residency-level training, published original work in the discipline, and passed a two-stage examination covering the science of how drugs behave in animals and how they should be used therapeutically.
The credential is easy to confuse with other certifications that happen to share the same acronym. This article concerns only the veterinary specialty. If you are looking for shorter definitions, our explainers on what DACVCP stands for and the meaning of the DACVCP designation cover the vocabulary, while this guide focuses on how the certification actually works from application to maintenance.
The Two-Phase Path to Board Certification
Certification requires completing both Phase I and Phase II. They are not interchangeable or optional stages. Phase I is the earlier examination, taken while a candidate is enrolled in or has completed an approved ACVCP residency. Phase II comes after a candidate has completed approved training, passed Phase I, and had their credentials approved.
| Feature | Phase I | Phase II |
|---|---|---|
| Format | 200 multiple-choice questions | Ten question groups: written response, multiple choice, fill-in-the-blank, extended matching |
| Structure | Two 100-question sessions | Two 100-point sessions (200 points total) |
| Ordinary schedule | Roughly 08:00-12:00 and 14:00-18:00 local time | Eight active hours |
| Prerequisite | Legal qualification to practice; enrolled in or completed approved residency; two references | Completed training, Phase I pass, approved credentials, two papers |
| 2026 date | May 19 | June 30 |
One detail trips up many candidates: the 200 on Phase II is a point total, not a question count. The ten groups carry weighted point values that sum to 200 across the two sessions. Do not assume it mirrors the 200-question structure of Phase I.
Training, Eligibility and the Publication Requirement
Phase I eligibility
To apply for Phase I you must be legally qualified to practice veterinary medicine and be enrolled in, or have completed, an approved ACVCP residency. The application requires two references. Approved institutional and alternate training routes are described on the ACVCP's Becoming a Resident and Residency Training Programs pages, which also publish broad residency learning outcomes. Those outcomes describe what training should accomplish; they do not function as an exam blueprint. For a deeper look at the training side, see our overview of DACVCP training, and for a consolidated checklist see DACVCP requirements and how to qualify.
Phase II credentials review
Phase II is gated by a credentials review. You need completed approved training, a Phase I pass, approved credentials, course documentation and transcripts, and two peer-reviewed papers accepted or published by February 1 of the examination year. The paper rules are specific:
- At least one paper must be original veterinary clinical pharmacology research.
- The other may be original research or an eligible evidence-based systematic review or meta-analysis.
- You must be first author on at least one paper.
- Neither paper may have been used for another specialty board.
- Publication must not predate the beginning of training by more than two years.
How Phase I Is Built and Delivered
Phase I consists of 200 multiple-choice questions split into two 100-question sessions, ordinarily held 08:00-12:00 and 14:00-18:00 local time. That is eight active examination hours, not counting the break between sessions. The questions are drawn from a basic-science and applied-pharmacology curriculum, and the heading list the ACVCP has published in its suggested Phase I blueprint (last revised December 2021) is the best publicly available guide to the topic spread.
Remote delivery with ExamSoft
The ACVCP's 2026 candidate notice states that both phases were administered remotely using ExamSoft. Candidates supply their own compatible Windows or Mac laptop running Examplify, with administrator privileges. Examinations are downloaded in encrypted form and unlocked with a proctor password, and examination mode blocks internet access, files and other applications. The ACVCP offers advance practice examinations so candidates can rehearse the software and become familiar with the question structure. Use them; a technical surprise on exam day is entirely avoidable.
The 2026 administration dates have passed, and a 2027 schedule has not been verified. Because this dated notice takes precedence over generic references to an on-site testing location, treat remote delivery as the most recent confirmed arrangement but check the current Candidate Information page before you plan. Our page on DACVCP exam dates and deadlines tracks the scheduling details.
How Phase II Differs
Phase II is a different kind of test. Rather than a single stream of multiple-choice items, it uses ten question groups with mixed response formats: written responses, multiple choice, fill-in-the-blank and extended matching. The groups are worth 200 points across two 100-point sessions, and the ordinary schedule again provides eight active hours.
The written-response component changes how you prepare. Recognizing the correct option is not enough; you must be able to construct and defend a pharmacologic argument. Expect to practice articulating dose selection logic, interpreting pharmacokinetic data, critiquing study design and justifying therapeutic choices in your own words.
The four examination subject categories listed on the current Phase II page are Therapeutics, Pharmacokinetics and Therapeutic Drug Monitoring, Experimental Design, Statistics and Analytical Methods, and Regulatory Pharmacology. The ACVCP does not publish current category percentages on that page. An older Phase II suggested blueprint (December 2021) contains historical question allocations, but those figures should not be treated as current weights. For a sense of how demanding these formats are in practice, read our difficulty guide.
The Content Map: Domains You Must Master
This site organizes preparation around 26 content headings. Domains 1 through 22 are the unweighted preparation headings from the ACVCP's suggested Phase I blueprint, last revised December 2021. Domains 23 through 26 are the four Phase II subject categories from the ACVCP's current Phase II examination page. The count of 26 is simply the number of supplied headings; it is not an official combined exam-domain count, and the legacy headings are dated preparation topics rather than a verified current or exhaustive outline. Our full walkthrough is in the complete guide to all 26 content areas.
The foundational science block (Domains 1-9)
Domains 1-4: Physiochemical characteristics, Pharmacodynamics, Drug movement, Pharmacokinetics
These domains form the quantitative backbone of the discipline. The blueprint retains the source spelling "Physiochemical" for the first heading.
- How an active pharmaceutical ingredient's physical and chemical properties shape absorption and disposition
- Receptor theory, dose-response relationships and mechanisms of drug action
- Membrane transport and the movement of drugs across biological barriers
- Compartmental and non-compartmental analysis and the parameters derived from each
Domains 5-9: Variability, routes, dosing forms, adverse events and therapeutic failure
These headings move from theory toward the real-world reasons a drug behaves differently from one patient to the next.
- Factors impacting drug movement and drug response, including species, age, disease and interactions
- Routes of administration and their consequences for onset and bioavailability
- Dosing forms and relevant drug delivery devices
- Adverse events and the causes of therapeutic failure
The organ-system and drug-class block (Domains 10-22)
Domains 10 through 22 apply the principles above to body systems and drug classes: Nervous System, Renal, Cardiovascular, Gastrointestinal, Reproduction, Endocrine, General and special senses, Control of inflammation/immunomodulation, Anticancer drugs, Fluid therapy, Anti-infectives, Botanical/Herbals, and Disinfectants/antiseptics. Notice how broad this is. A candidate is expected to reason about renal handling of drugs one day and antimicrobial pharmacology the next, and to know where botanicals and antiseptics fit alongside conventional therapeutics.
Domains 23-26: The Phase II categories
These four headings reflect the higher-order skills Phase II tests.
- Therapeutics: choosing and justifying treatment across species and conditions
- Pharmacokinetics and Therapeutic Drug Monitoring: interpreting concentration data and adjusting regimens
- Experimental Design, Statistics and Analytical Methods: evaluating study validity and analytical approaches
- Regulatory Pharmacology: the framework governing drug approval and use
Nothing in the published materials gives a fixed weighting among these headings, so avoid study plans that assume one domain is "worth" a stated percentage. When you want a condensed review, our one-page DACVCP cheat sheet distills the high-yield facts.
Fees, Deadlines and the Five-Year Window
The published 2026 fee structure
The ACVCP's Candidate Deadlines and Fees page lists the following for the published 2026 cycle:
| Item | Fee (USD) |
|---|---|
| Phase I application | 75 |
| Phase I examination | 200 |
| Phase II credentials review | 250 |
| Phase II examination | 300 |
A few cautions apply. Retakes require the respective examination fee. The general fee page permits refunds only for extenuating circumstances accepted by the Board, while the individual phase pages describe examination fees as nonrefundable, so assume no refund. Separately, the Becoming a Resident page calls a USD 75 charge a first-year candidate registration fee. The public pages do not establish whether this is the same as or additional to the Phase I application charge, so confirm with the ACVCP before budgeting. These exam fees are only part of the picture; residency costs and lost time dominate the real expense, which we break down in our DACVCP certification cost guide.
Deadlines and the eligibility window
Applications are ordinarily due October 1 before the examination year, and intent to sit is due by February 1. The currently dated checklist covers October 1, 2025 and February 1, 2026. Both phases must be passed within a five-year eligibility period beginning with the first eligible examination year after Phase I approval. The ACVCP's own example: approval in December 2025 permits examinations in 2026 through 2030. This is an examination eligibility window, not a credential renewal term.
Sequencing Domains Across Your Preparation
The most useful structure for studying is one that follows the logic of the content map. Foundational pharmacokinetics and pharmacodynamics underpin nearly every other domain, so they belong first. Below is one way to sequence Phase I preparation, tied to the actual domains. For a full strategy, see our DACVCP study guide.
Quantitative foundations
- Domains 1-4: physiochemical properties, pharmacodynamics, drug movement and pharmacokinetics
- Work calculation problems until the equations feel automatic
Sources of variability
- Domains 5-9: variability factors, routes, dosing forms, adverse events, therapeutic failure
- Connect each to the pharmacokinetic principles from Block 1
Organ systems and drug classes
- Domains 10-22, grouped by system; give extra time to Anti-infectives and Anticancer drugs given their breadth
- Include Botanical/Herbals and Disinfectants/antiseptics, which are easy to neglect
Phase II synthesis
- Domains 23-26: practice written reasoning, study critique and regulatory frameworks
- Rehearse in the ExamSoft environment using the ACVCP practice examinations
You can test yourself against realistic question formats on our practice test site, which helps reveal which blocks need more time.
Who Hires Clinical Pharmacologists
Veterinary clinical pharmacologists work where drug knowledge is a core competency. The training and credentialing path is oriented toward academic and research settings, so university colleges of veterinary medicine are a natural home, combining teaching, research and clinical consultation. The skill set also fits the pharmaceutical and animal health industry, where understanding pharmacokinetics, study design and regulatory pharmacology matters for drug development. Regulatory bodies and contract research organizations also draw on the expertise, as do veterinary teaching hospitals that run clinical pharmacology services and therapeutic drug monitoring programs.
We do not publish specific salary figures here because verified numbers are not available to us; compensation varies widely by sector, with academic, industry and government roles structured very differently. For discussion of how earnings and career paths compare, see our DACVCP salary guide, our look at DACVCP jobs, and our cost-benefit analysis of whether the certification is worth it.
Maintaining the Credential
The ACVCP's current Committees page confirms that a Maintenance of Certification committee administers recertification. The linked detailed page requires authorization and was not accessible when this article was prepared, so current renewal hours, fees and intervals cannot be stated.
There is historical context. Indexed text from the ACVCP Bylaws, approved June 2018, describes review of maintenance records every two years toward maintenance at ten years. However, the complete legacy file could not be retrieved, and its current applicability and the rules for affected Diplomates remain unverified. Treat that as background, not as a current requirement. If you are approaching certification, ask the ACVCP directly for the current Maintenance of Certification policy.
Key Takeaway
Before you commit, verify three things directly with the ACVCP: the current-year exam schedule and delivery method, the current blueprint documents (which could not be retrieved for this article), and the active Maintenance of Certification policy. Public materials on these points are dated or access-restricted.
Frequently Asked Questions
It stands for Diplomate, American College of Veterinary Clinical Pharmacology. It identifies a veterinarian who has earned board certification from the ACVCP in veterinary clinical pharmacology. See also what DACVCP certification is for a fuller definition.
Two. Phase I and Phase II must both be passed, within a five-year eligibility period that begins with the first eligible examination year after Phase I approval.
The ACVCP says passing points are recommended by the Examination Committee and ad hoc reviewers for Board approval. A fixed numerical pass mark was not verified. Our passing score page explains what is and is not known.
A current pass rate was not verified in the public materials we reviewed, so we do not quote one. See the pass rate discussion for what can responsibly be said.
Yes. Phase II credentials review requires two peer-reviewed papers accepted or published by February 1 of the examination year, with at least one original veterinary clinical pharmacology research paper and first authorship on at least one.